New molecules in the treatment of inflammatory bowel disease

Baumgart, 2007, Inflammatory bowel disease: cause and immunobiology, Lancet, 369, 1627, 10.1016/S0140-6736(07)60750-8 Engel, 2010, New pathophysiological insights and modern treatment of IBD, J Gastroenterol, 45, 571, 10.1007/s00535-010-0219-3 Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804 D’Haens, 1999, Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial, Gastroenterology, 116, 1029, 10.1016/S0016-5085(99)70005-3 Hanauer, 2002, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 Chaparro, 2011, Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose escalation in patients losing response, J Clin Gastroenterol, 45, 113, 10.1097/MCG.0b013e3181ebaef9 Chaparro, 2012, Effectiveness of infliximab after adalimumab failure in Crohn's disease, World J Gastroenterol, 18, 5219 Chaparro, 2012, Long-term durability of response to adalimumab in Crohn's disease, Inflamm Bowel Dis, 18, 685, 10.1002/ibd.21758 Hutas, 2008, Golimumab, a fully human monoclonal antibody against TNFalpha, Curr Opin Mol Ther, 10, 393 Lonberg, 2005, Human antibodies from transgenic animals, Nat Biotechnol, 23, 1117, 10.1038/nbt1135 Shealy, 2010, Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha, MAbs, 2, 428, 10.4161/mabs.12304 Sandborn, 2014, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 85, 10.1053/j.gastro.2013.05.048 Sandborn, 2014, Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 96, 10.1053/j.gastro.2013.06.010 Marshall, 2001, LDP-02 (Millenium), Curr Opin Investig Drugs, 2, 502 Tsuzuki, 1996, Alpha 4 integrin plays a critical role in early stages of T lymphocyte migration in Peyer's patches of rats, Int Immunol, 8, 287, 10.1093/intimm/8.3.287 Tilg, 2010, Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease, Curr Opin Investig Drugs, 11, 1295 Souza, 1999, Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease, Gut, 45, 856, 10.1136/gut.45.6.856 Gordon, 2001, A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease, Gastroenterology, 121, 268, 10.1053/gast.2001.26260 Targan, 2007, Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial, Gastroenterology, 132, 1672, 10.1053/j.gastro.2007.03.024 Ford, 2011, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 106, 644, 10.1038/ajg.2011.73 Yousry, 2006, Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy, N Engl J Med, 354, 924, 10.1056/NEJMoa054693 Haanstra, 2013, Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis, J Immunol, 190, 1961, 10.4049/jimmunol.1202490 Milch, 2013, Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype, J Neuroimmunol, 264, 123, 10.1016/j.jneuroim.2013.08.011 Hesterberg, 1996, Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7, Gastroenterology, 111, 1373, 10.1053/gast.1996.v111.pm8898653 Feagan, 2000, An ascending dose of a humanized alpha 4 beta 7 antibody in ulcerative colitis, Gastroenterology, 118, A874, 10.1016/S0016-5085(00)85637-1 Feagan, 2005, Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin, N Engl J Med, 352, 2499, 10.1056/NEJMoa042982 Feagan, 2008, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin, Clin Gastroenterol Hepatol, 6, 1370, 10.1016/j.cgh.2008.06.007 Parikh, 2012, Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study, Inflamm Bowel Dis, 18, 1470, 10.1002/ibd.21896 Parikh, 2013, Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease, Inflamm Bowel Dis, 19, 1691, 10.1097/MIB.0b013e318281f538 Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734 Sandborn, 2013, Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, 369, 711, 10.1056/NEJMoa1215739 Sands, 2013, Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised placebo-controlled, double-blind, multicenter trial, J Crohns Colitis, 7, S5, 10.1016/S1873-9946(13)60012-4 Hanauer, 2014, Long-term efficacy of vedolizumab therapy for Crohn's disease, United Eur Gastroenterol J, 2014, A66 Sands, 2014, Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology, 147, 618, 10.1053/j.gastro.2014.05.008 Hanauer, 2014, Long-term efficacy of vedolizumab therapy for Crohn's disease, United Eur Gastroenterol J, 2, A66 Farkas, 2013, Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy, Scand J Gastroenterol, 48, 1394, 10.3109/00365521.2013.845906 Rinaudo-Gaujous, 2013, Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases, Aliment Pharmacol Ther, 38, 914, 10.1111/apt.12477 Malik, 2009, Controlling the cost of innovative cancer therapeutics, Nat Rev Clin Oncol, 6, 550, 10.1038/nrclinonc.2009.113 Weise, 2012, Biosimilars: what clinicians should know, Blood, 120, 5111, 10.1182/blood-2012-04-425744 Crommelin, 2003, Shifting paradigms: biopharmaceuticals versus low molecular weight drugs, Int J Pharm, 266, 3, 10.1016/S0378-5173(03)00376-4 Gomollon, 2015, Biosimilars in inflammatory bowel disease: ready for prime time, Curr Opin Gastroenterol, 31, 290, 10.1097/MOG.0000000000000184 European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002778/WC500151491.pdf [accessed 01.09.15]. Yoo, 2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, 72, 1613, 10.1136/annrheumdis-2012-203090 Park, 2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, 72, 1605, 10.1136/annrheumdis-2012-203091 Feagan, 2014, The challenge of indication extrapolation for infliximab biosimilars, Biologicals, 42, 177, 10.1016/j.biologicals.2014.05.005 Fiorino, 2014, The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper, Autoimmun Rev, 13, 751, 10.1016/j.autrev.2014.02.004 Ebbers, 2014, Biosimilars: in support of extrapolation of indications, J Crohns Colitis, 8, 431, 10.1016/j.crohns.2014.02.007 Dewit, 2012, Results of a phase II, randomized, double blind, controlled trial of the efficacy of active therapeutic immunization with TNF-kinoid in patients with moderate to severe Crohn's disease with secondary resistance to TNF antagonist, Gastroenterology, 142, S, 10.1016/S0016-5085(12)62179-9 Amiot, 2015, Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases, Therap Adv Gastroenterol, 8, 66, 10.1177/1756283X14558193 Michelsen, 2013, HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses, Inflamm Bowel Dis, 19, 151 Leonardi, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, 371, 1665, 10.1016/S0140-6736(08)60725-4 Papp, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet, 371, 1675, 10.1016/S0140-6736(08)60726-6 Gottlieb, 2009, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial, Lancet, 373, 633, 10.1016/S0140-6736(09)60140-9 Sandborn, 2008, A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease, Gastroenterology, 135, 1130, 10.1053/j.gastro.2008.07.014 Sandborn, 2012, Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N Engl J Med, 367, 1519, 10.1056/NEJMoa1203572 Danese, 2014, Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: a phase 2a randomized placebo-controlled study, Gastroenterology, 146, s149, 10.1016/S0016-5085(14)60530-8 Ito, 2004, A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease, Gastroenterology, 126, 989, 10.1053/j.gastro.2004.01.012 Reinisch, 2014, Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: results from an anti-IL-13 antibody study, J Crohns Colitis, 2014, S283, 10.1016/S1873-9946(14)60636-X Van Deventer, 1997, Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group, Gastroenterology, 113, 383, 10.1053/gast.1997.v113.pm9247454 Fedorak, 2000, Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group, Gastroenterology, 119, 1473, 10.1053/gast.2000.20229 Schreiber, 2000, Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group, Gastroenterology, 119, 1461, 10.1053/gast.2000.20196 Colombel, 2001, Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease, Gut, 49, 42, 10.1136/gut.49.1.42 Sands, 2002, Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease, Aliment Pharmacol Ther, 16, 399, 10.1046/j.1365-2036.2002.01179.x Herrlinger, 2006, Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease, Am J Gastroenterol, 101, 793, 10.1111/j.1572-0241.2005.00356.x Pena-Rossi, 2008, Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase ii study of subcutaneous interferon-beta-la in moderately active ulcerative colitis, Aliment Pharmacol Ther, 28, 758, 10.1111/j.1365-2036.2008.03778.x Musch, 2005, Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial, Clin Gastroenterol Hepatol, 3, 581, 10.1016/S1542-3565(05)00208-9 Vermeire, 2014, Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial, Lancet, 384, 309, 10.1016/S0140-6736(14)60661-9 Walters, 2010, Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease, J Pharmacol Exp Ther, 335, 61, 10.1124/jpet.110.169714 Papadakis, 2001, CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease, Gastroenterology, 121, 246, 10.1053/gast.2001.27154 Keshav, 2013, A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease, PLoS ONE, 8, e60094, 10.1371/journal.pone.0060094 Varrin-Doyer, 2014, Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis, Exp Neurol, 262, 66, 10.1016/j.expneurol.2014.04.002 D’Haens, 2014, A phase ii study of laquinimod in Crohn's disease, Gut Beunk, 2013, Role of mast cells in mucosal diseases: current concepts and strategies for treatment, Expert Rev Clin Immunol, 9, 53, 10.1586/eci.12.82